Dianthus Therapeutics, Inc. (DNTH)
| Market Cap | 4.68B +566.4% |
| Revenue (ttm) | 1.34M -79.5% |
| Net Income | -173.66M |
| EPS | -4.17 |
| Shares Out | 54.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 574,404 |
| Open | 91.24 |
| Previous Close | 90.42 |
| Day's Range | 83.56 - 91.24 |
| 52-Week Range | 16.64 - 96.50 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 121.17 (+41.47%) |
| Earnings Date | May 5, 2026 |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio... [Read more]
Financial Performance
In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $121.17, which is an increase of 41.47% from the latest price.
News
Dianthus price target raised to $125 from $123 at Raymond James
Raymond James raised the firm’s price target on Dianthus (DNTH) to $125 from $123 and keeps a Strong Buy rating on the shares. Dianthus’ Q1 update highlighted pipeline progress including
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDA...
Dianthus reports Q1 EPS (85c), consensus ($1.10)
Reports Q1 revenue $463,000, consensus $358,690. “Q1 of this year was a pivotal period for Dianthus (DNTH) as we were able to make an early GO decision in PART A
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to tr...
Dianthus treatment of myasthenia gravis gets orphan status
Dianthus (DNTH) Therapeutics was granted FDA orphan designation for claseprubart as a treatment of myasthenia gravis, according to a post to the agency’s website. Published first on TheFly – the
Dianthus initiated with an Outperform at Wolfe Research
Wolfe Research analyst Andy Chen initiated coverage of Dianthus (DNTH) with an Outperform rating and $98 price target. The firm notes that the company’s Claseprubart is heading toward three diseases
Dianthus initiated with an Overweight at Wells Fargo
Wells Fargo analyst Sadia Rahman initiated coverage of Dianthus (DNTH) with an Overweight rating and $135 price target The firm says the company’s claseprubart “stands out” in the complement inhibitor
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus price target raised to $103 from $80 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Dianthus (DNTH) to $103 from $80 and keeps an Outperform rating on the shares. Following the completion of the recent
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus price target raised to $80 from $55 at Wedbush
Wedbush raised the firm’s price target on Dianthus (DNTH) to $80 from $55 and keeps an Outperform rating on the shares. Heading into the CAPTIVATE interim readout, the firm anticipated
Dianthus price target raised to $132 from $67 at Baird
Baird analyst Colleen Kusy raised the firm’s price target on Dianthus (DNTH) to $132 from $67 and keeps an Outperform rating on the shares. The firm’s target increase reflects its
Dianthus upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Ryan Deschner upgraded Dianthus (DNTH) to Strong Buy from Outperform with a price target of $123, up from $63. The firm is “increasingly bullish” on claseprubart following
Dianthus price target raised to $130 from $100 at Clear Street
Clear Street analyst Bill Maughan raised the firm’s price target on Dianthus (DNTH) to $130 from $100 and keeps a Buy rating on the shares. The firm is citing the
Dianthus announces $400M common stock offering
Dianthus (DNTH) Therapeutics announced that it has commenced an underwritten public offering of $400M of shares of its common stock or, in lieu of common stock to certain investors that
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus price target raised to $98 from $81 at Jefferies
Jefferies analyst Maury Raycroft raised the firm’s price target on Dianthus (DNTH) to $98 from $81 and keeps a Buy rating on the shares after the company said the proportion
Dianthus price target raised to $132 from $67 at Baird
Baird raised the firm’s price target on Dianthus (DNTH) to $132 from $67 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source for
Dianthus a ‘viable takeout target,’ says TD Cowen
TD Cowen notes that Dianthus (DNTH) has announced an earlier than anticipated “Go” decision for its Phase 3 CAPTIVATE study of claseprubart in CIDP following a Part A interim analysis
Dianthus price target raised to $125 from $65 at LifeSci Capital
LifeSci Capital raised the firm’s price target on Dianthus (DNTH) to $125 from $65 and keeps an Outperform rating on the shares. Dianthus reported an earlier-than-expected “Go” decision in its
Dianthus rises 26.3%
Dianthus (DNTH) is up 26.3%, or $17.15 to $82.35. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on
Dianthus price target raised to $130 from $47 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Dianthus (DNTH) to $130 from $47 and keeps a Buy rating on the shares. Based on the positive data
Dianthus price target raised to $145 from $125 at Oppenheimer
Oppenheimer raised the firm’s price target on Dianthus (DNTH) to $145 from $125 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source for
Dianthus Therapeutics Transcript: Study result
An interim analysis of the CAPTIVATE phase 3 trial in CIDP led to an early go decision, with efficacy surpassing expectations and a strong safety profile. Study design changes will expedite completion, and the program is well positioned for future milestones and competitive advantage.